BioSpace News Archive

Drug Development

BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer’s Disease

The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain

July 5, 2018
·
9 min read
Business

Martin Shkreli Speaks from Prison About the Biopharma Industry

Martin Shkreli has been blogging about the biopharma industry from prison.

July 5, 2018
·
2 min read
·
Alex Keown
Drug Development

Merz Snags FDA Approval for Chronic Drooling Treatment

Merz Neurosciences announced that the U.S. Food and Drug Administration approved a treatment for chronic drooling in adults.

July 5, 2018
·
2 min read
·
Alex Keown
Job Trends

Another Biotech Company Setups Up Shop in New Jersey

Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.

July 5, 2018
·
2 min read
·
Alex Keown
Could Augmented Reality Benefit Patient Experience in Managing Healthcare?

More and more biopharma companies are moving toward the use of artificial intelligence and machine learning as they develop therapies for a wide range of diseases.

July 5, 2018
·
2 min read
·
Alex Keown